Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group”) (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that its subsidiary, Psyence Biomedical Ltd (“Pubco”), has entered into a definitive securities purchase agreement (the “Securities Purchase Agreement”) providing for up to US$10 million in funding through the issuance of up to four senior secured convertible notes (the “Notes” and “Note Financing”, respectively) with a US based investment firm (the “Purchaser”).
Related news for (PSYGF)
- Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
- Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
- Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division